PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years.
"We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physician, biopharmaceutical industry executive and sector investor," said Jacob Harel, PolyPid's Chairman. "We look forward to leveraging Dr. Tweezer-Zaks' vast expertise across the business development, clinical, R&D, and financial functions as we approach critical clinical and regulatory milestones as well as potential commercialization of our late-stage product candidate, D-PLEX100, for the prevention of surgical site infections ("SSIs"). I would also like to thank Anat for her distinguished service and counsel as a member of PolyPid's Board since April 2008. She has been instrumental in the Company's evolution to a fully integrated biopharmaceutical company."
Dr. Tweezer-Zaks said, "I am excited to be joining the PolyPid Board at this important time for the company. I believe that D-PLEX100 has the potential to significantly improve patient surgical outcomes and reduce the substantial burden on the healthcare system that SSIs pose. I look forward to working collaboratively with the Board and the management team to best position PolyPid for success as we approach potential approval and commercialization."
Anat Tsour Segal said, "I feel privileged and honored to have served PolyPid for the past 15 years from its very inception. PolyPid brings a transformational and vital technology to the world, that has the potential to make a real difference in the prevention of post-surgical infections as well as in other areas where slow, local, controlled drug delivery is effective. I wish to thank the Board and the team for 15 wonderful years, and I wish the Company much ...
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.